Business
Vaxcyte Announces Pricing of $550 Million Public Offering
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expense
About this update from Vaxcyte, Inc.
[{"type":"image","alt":"Vaxcyte, Inc.","displaySize":"","headline":null,"caption":"Vaxcyte, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4603e333819538d7d741e3ecc95e1d72"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UD9p7QfAhQocG_mwSinWcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4603e333819538d7d741e3ecc95e1d72","width":300,"height":116}},"lazy":false},{"type":"text","content":"SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common stock. Vaxcyte is selling 11,000,000 shares of common stock in the offering at a public offering price of $50.00 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be $550 million, before deducting underwriting discounts and commissions and other offering expenses. All shares of common stock to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.","length":791,"tagName":"p"},{"type":"text","content":"The offering is expected to close on February 2, 2026, subject to the satisfaction of customary closing conditions.","length":115,"tagName":"p"},{"type":"text","content":"BofA Securities, Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers, Mizuho is acting as a book-runner, and BTIG and Needham & Company are acting as joint lead co-managers for the offering.","length":252,"tagName":"p"},{"type":"text","content":"A shelf registration statement relating to the offered securities was filed with the Securities and Exchange Commission (SEC) and was automatically effective upon filing on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed, and a final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the ac...